TABLE 1: Lists of Issued Written Requests (WRs) between Jan. 1, 2001 and Dec. 31, 2019

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Drug Name** | **Initial Request Date** | **Current Status** | **Approval of Age Range (year)** | **Languages added to labeling from WR studies** |
| **Naxitamab** | 6/26/2019 | Study data not yet completed |  |  |
| **Abemaciclib** | 6/7/2019 | Study data not yet completed |  |  |
| **BXQ-350** | 3/12/2019 | Study data not yet completed |  |  |
| **Cobimetinib** | 12/11/2018 | Study data not yet completed |  |  |
| **Venetoclax** | 7/5/2018 | Study data not yet completed |  |  |
| **Palbociclib** | 7/3/2018 | Study data not yet completed |  |  |
| **Midostaurin (Rydapt)** | 3/22/2018 | Study data not yet completed |  |  |
| **Trabectedin (Yondelis)** | 11/7/2017 | Exclusivity granted |  | Section 8.4 (Yondelis) |
| **Eribulin Mesylate (Halaven)** | 7/8/2016 | Study data not yet completed |  |  |
| **Dabrafenib (Tafinlar)** | 3/1/2016 | Study data not yet completed |  |  |
| **Trametinib (Mekinist)** | 3/1/2016 | Study data not yet completed |  |  |
| **Ruxolitinib** | 12/11/2015 | Study data not yet completed | >=12 |  |
| **Pomalidomide** | 11/20/2015 | Active, not recruiting |  |  |
| **Carfilzomib (Kyprolis)** | 3/17/2015 | Study data not yet completed |  |  |
| **nab-paclitaxel** | 10/29/2014 | Exclusivity granted |  | Section 8.4 (Abraxane) |
| **Lenalidomide (Revlimid)** | 9/14/2014 | Completed, but expired |  |  |
| **Cabazitaxel (Jevtana)** | 3/20/2012 | Exclusivity granted |  | Section 8.4 (Jevtana) |
| **Crizotinib (Xalkori)** | 11/28/2011 | Completed, but expired |  |  |
| **Bortezomib (Velcade)** | 4/27/2010 | Exclusivity granted |  | Section 8.4 (Velcade) |
| **Everolimus (RAD001, Afinitor)** | 4/1/2010 | Exclusivity granted | >=1 | Section 1.5, 6.1, 8.4, s 12.3 and 14.5 (Afinitor) |
| **Bendamustine hcl (Treanda)** | 1/19/2010 | Exclusivity granted |  | Section 8.4 (Treanda) |
| **Decitabine (Dacogen)** | 6/19/2009 | Exclusivity denied |  |  |
| **Nilotinib (Tasigna)** | 6/19/2009 | Exclusivity granted | >=1 | Section 1.3, 2.1, 5.14, 6.1, 8.4, and 14.5 (Tasigna) |
| **Docetaxel (Taxotere)** | 6/11/2007 | Exclusivity granted |  | Section 5.13, 8.4, 12.3 (Taxotere) |
| **Daunorubicin (Daunomycin)** | 11/8/2006 | NA/Unable to find |  |  |
| **Daunorubicin (Daunoxome)** | 11/8/2006 | NA/Unable to find |  |  |
| **Sunitinib malate (Sutent)** | 10/23/2006 | Exclusivity granted |  | Section 8.4 (Sutent) |
| **Methotrexate (MTX)** | 9/22/2006 | No exclusivity granted |  | Section 5.1 and 8.4 (Methotrexate) |
| **Capecitabine (Xeloda)** | 3/16/2005 | Exclusivity granted |  | Section 8.4 (Xeloda) |
| **Oxaliplatin (ELOXATIN)** | 12/9/2004 | Exclusivity granted |  | Section 8.4 (Eloxatin) |
| **Vincristine** | 8/4/2004 | Study withdrawal |  |  |
| **Dactinomycin** | 8/3/2004 | No exclusivity granted | all age | Section 1.1-1.4, 8.4, and 12.3 (Cosmegen) |
| **Zoledronic acid (Zometa)** | 8/19/2002 | Exclusivity granted |  | Section 8.4 (Zometa) |
| **Epirubicin HCl (Ellence)** | 2/19/2002 | Study terminated |  |  |
| **Fludarabine phosphate (Fludara)** | 11/9/2001 | Exclusivity granted |  | Section 8.4 (phosphate) |
| **Anastrozole (Arimidex)** | 5/9/2001 | NA/Unable to find |  |  |
| **Carboplatin (Paraplatin)** | 4/11/2001 | Exclusivity granted |  |  |
| **Irinotecan HCl (Camptosar)** | 1/22/2001 | Exclusivity granted |  | Section 8.4 (Camptosar) |
| **Gemtuzumab ozogamicin (Mylotarg)** | 1/10/2001 | NA/Unable to find |  |  |
| **Temozolomide (Temodar)** | 1/9/2001 | Exclusivity granted |  | Section 8.4 (Temodar) |
| **Vinorelbine tartrate (Navelbine)** | 1/9/2001 | Exclusivity granted |  | Section 8.4 (Navelbine) |
| **Gemcitabine HCl(Gemzar)** | 1/9/2001 | Exclusivity granted |  | Section 8.4 (Gemzar) |